Apellis Pharmaceuticals Valuation
| APLS Stock | USD 31.91 1.14 3.70% |
At this time, the firm appears to be undervalued. Apellis Pharmaceuticals shows a prevailing Real Value of $39.77 per share. The current price of the firm is $31.91. Our model approximates the value of Apellis Pharmaceuticals from analyzing the firm fundamentals such as profit margin of (0.35) %, and Return On Equity of -1.07 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Apellis Pharmaceuticals' valuation include:
Price Book 16.1419 | Enterprise Value 3.9 B | Enterprise Value Ebitda (12.12) | Price Sales 5.3516 | Enterprise Value Revenue 5.4545 |
Undervalued
Today
Please note that Apellis Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Apellis Pharmaceuticals is based on 3 months time horizon. Increasing Apellis Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Apellis stock is determined by what a typical buyer is willing to pay for full or partial control of Apellis Pharmaceuticals. Since Apellis Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Apellis Stock. However, Apellis Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 31.91 | Real 39.77 | Target 71.71 | Hype 30.4 | Naive 31.06 |
The intrinsic value of Apellis Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Apellis Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Apellis Pharmaceuticals helps investors to forecast how Apellis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Apellis Pharmaceuticals more accurately as focusing exclusively on Apellis Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Apellis Pharmaceuticals' intrinsic value based on its ongoing forecasts of Apellis Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Apellis Pharmaceuticals' closest peers.
Apellis Pharmaceuticals Cash |
|
Apellis Valuation Trend
Apellis Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Apellis Pharmaceuticals' financial worth over time. Using both Apellis Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Apellis Revenue by Product
Apellis Pharmaceuticals Total Value Analysis
Apellis Pharmaceuticals is presently expected to have valuation of 3.9 B with market capitalization of 3.83 B, debt of 110.93 M, and cash on hands of 852.8 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Apellis Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.9 B | 3.83 B | 110.93 M | 852.8 M |
Apellis Pharmaceuticals Investor Information
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.03. Apellis Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Apellis Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Apellis Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Apellis Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Apellis Pharmaceuticals has an asset utilization ratio of 50.28 percent. This implies that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that Apellis Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Apellis Pharmaceuticals Ownership Allocation
Apellis Pharmaceuticals holds a total of 124.39 Million outstanding shares. The majority of Apellis Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Apellis Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Apellis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Apellis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly fourteen million two hundred thirty thousand five hundred fifty-nine invesors are currently shorting Apellis Pharmaceuticals expressing very little confidence in its future performance.Apellis Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M.About Apellis Pharmaceuticals Valuation
The stock valuation mechanism determines Apellis Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Apellis Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Apellis Pharmaceuticals. We calculate exposure to Apellis Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Apellis Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 338.1 M | 355 M | |
| Pretax Profit Margin | (1.33) | (1.39) | |
| Operating Profit Margin | (1.30) | (1.37) | |
| Net Loss | (1.33) | (1.40) | |
| Gross Profit Margin | 0.85 | 0.99 |
Apellis Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Apellis Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 118.7 M |
Apellis Pharmaceuticals Current Valuation Indicators
Apellis Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Apellis Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Apellis Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Apellis Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Apellis Pharmaceuticals' worth.Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.